Macquarie Group’s Lineage Cell Therapeutics LCTX Stock Holding History

Macquarie Group’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-4,343	Closed	-$8K	–	2274
2017 Q4	$8K	Buy	+4,343	New	+$9.48K	﹤0.01%	2309

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

IndexIQ Advisors New York $2.82B AUM 12.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group's LCTX Position: Q1 2018 in Review

Macquarie Group sold out of Lineage Cell Therapeutics (LCTX) in Q1 2018, closing a stake of 4,343 shares — an estimated $8K sold.

Macquarie Group first reported a position in LCTX in Q4 2017 and held it in 1 quarter. The position peaked at $8K in Q4 2017. 115 funds tracked by Wall St. Rank hold LCTX as of Q1 2018.

Macquarie Group reported no remaining Lineage Cell Therapeutics position as of Q1 2018 after selling out during the quarter.
Macquarie Group sold 4,343 Lineage Cell Therapeutics shares in Q1 2018, an estimated $8K.
Macquarie Group first reported a position in Lineage Cell Therapeutics in Q4 2017 and held it in 1 quarter.
Macquarie Group's Lineage Cell Therapeutics position peaked at $8K in Q4 2017.
115 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2018.

Based on Macquarie Group's 13F filing for Q1 2018, filed 11 May 2018.